Kornimate/medical-research-clean huggingface dataset:
cryoablation combined with pd-1 antibody and bevacizumab for hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: to explore the safety and efficacy of cryoablation combined with pd-1 antibody and bevacizumab for patients with hepatocellular carcinoma resistance to pd-1/l1 antibody.


Eligibility criteria:
inclusion criteria: 1. age between 18 and 80 years old, and expected survival is longer than 3 months 2. clinically or pathologically diagnosed as primary hepatocellular carcinoma 3. disease progression assessed according to mrecist criteria after pd-1/l1 antibody treatment 4. child-pugh score of liver function a/b (\< 7) 5. at least one lesion is suitable for mrecist assessment 6. strength score (ecog): 0-1 7. the patient and/or family members agree to join the clinical trial and sign the informed consent form exclusion criteria: 1. patients whose tumor lesions are not suitable for ablation as assessed by the surgeon 2. tumor burden greater than ≥70%, or tumor is not suitable for mrecist standard evaluation 3. patients with chronic viral hepatitis (hepatitis b, hepatitis c) have a viral load greater than 10\^4 before receiving treatment or do not continue to take antiviral drugs regularly 4. pregnant patients 5. combined with other malignant tumors, or have a history of other malignant tumors within 3 years 6. active autoimmune disease, confirmed immunodeficiency, history of systemic steroid medication 7. severe renal dysfunction: creatinine (cr) \> 2 mg/dl or creatinine clearance (ccr) \<30 ml/min, severe heart, lung, brain and other important organ diseases 8. history of gastrointestinal bleeding within 3 months 9. unable to cooperate with ablation surgery 10. severe gastroesophageal varices
pharmacokinetic and pharmacodynamic evaluation of linezolid administered intravenously in mrsa-positive, morbidly obese patients with pneumonia

Conditions: Pneumonia

Summary: the objectives of the study are: (i) to evaluate the proportion of patients who attain a t\>mic (minimum inhibitory concentration) of 100% and the time frame in which they do so. the investigators therefore plan to measure unbound linezolid trough concentrations before administration of the second, third, fourth and fifth dose. furthermore, the investigators will assess the auc0 - 24h/mic in all study subjects. therefore, multiple plasma samples will be drawn after the fourth or fifth dose, when steady state conditions are reached. (ii) to describe the pharmacokinetic variability of unbound linezolid concentrations in this cohort using a population pharmacokinetic model and to assess the expected probability of target attainment (pta) by mic against mrsa. twenty adult, mrsa-positive, morbidly obese patients with clinically and radiologically documented pneumonia are to be included. therefore, a multi-centre, international observational study is necessary. given the specific target population this study is not feasible in a single-centre approach. the goal is to find up to 6 centres that anticipate including 3 to 4 patients in the study within a time frame of one year. included patients should receive at least 6 doses of linezolid. linezolid must be administered intravenously (iv) over a one hour controlled infusion (with use of a volumetric infusion pump).


Eligibility criteria:
* bmi \>35 * radiographically and clinically documented pneumonia and one of the following: * the patient is mrsa screen-positive and is as such at high risk for mrsa pneumonia (mic for linezolid is known or possible to assess) * the patient has a baseline respiratory tract sample positive for mrsa; mrsa pneumonia is likely * empiric therapy without linezolid is initiated (no obvious indication for mrsa involvement), but the patient is switch to linezolid therapy once culture results demonstrate mrsa as pathogen. cave: the patients must be included in the study prior to the moment the first trough sample must be drawn. as such, patients becoming mrsa-positive after \>1 dose of linezolid cannot be included in the study. * decision to start treatment with linezolid for at least 3 days (6 doses of 600 mg). * patient is colonized or infected with mrsa (at any site) and it must be possible to sent a fresh isolate to the central laboratory for microbiology. * written informed consent by the patient or his/her legal representative. exclusion: contraindications as described in the summary of product characteristics (spc).

Keywords: pneumonia
using rapid cine-mri for monitoring moving and deforming tumors

Conditions: Lung Cancer

Summary: in this study, the researchers investigate the feasibility of using rapid cine mr imaging to provide both offline and online soft-tissue-based image guidance. such images will provide a significantly more complete picture of the spatial and temporal changes in thoracic anatomy. this more complete information will lay the groundwork for better radiotherapy planning and dose delivery in the presence of respiratory motion.

rapid mri scans from stage i-iv non-small-cell lung cancer (nsclc) patients will be acquired. mr acquisition will be performed without extrinsically administered contrast, using a balanced turbo field echo (tfe) sequence and commercially available coils.

Eligibility criteria:
inclusion criteria: * ajcc stage i, ii, iii or iv non-small-cell lung cancer to be treated using radiotherapy will be eligible for this study. * any types and amounts of prior therapy will be allowed for this study. * subjects must be greater than or equal to 18 years of age. there are no gender or ethnic restrictions. * ability to understand and the willingness to sign a written informed consent document. * able to tolerate supine position * ecog performance status of 3 or less exclusion criteria: * mri-incompatible metallic implants, embedded metallic objects, implanted biomedical devices e.g., cardiac pacemakers * women who are pregnant or trying to get pregnant * pain in supine position
drug-drug interaction study of gefitinb on apatinib in nsclc patients

Conditions: NSCLC

Summary: the primary objective of the study was to assess the effect of gefitinib on the pharmacokinetics of apatinib mesylate in lung cancer patients. the secondary objective of the study was to assess the pharmacokinetics of gefitinib, and to assess the safety of apatinib mesylate and gefitinib administered in lung cancer patients.


Eligibility criteria:
inclusion criteria: 1. 18-75 years of age. 2. ecog performance status: level 0\~1; 3. anticipated life expectancy ≥ 12 weeks; 4. lung cancer patients; 5. major organs in good function; 6. agree to take approved method of contraception during the clinical trail and 8 weeks after the last dose of apatinib. female subject should be negative in the pregnancy test; 7. able to comprehend and willing to sign an informed consent form (icf) exclusion criteria: 1. history of drug allergy, or allergic to apatinib or gefitinib or ingredients; 2. squamous cancer, small-cell lung cancer; 3. symptomatic central nervous system (cns) metastases 4. hypertension and couldn't be controlled with medicine; 5. coagulation disorders; 6. clinical significant bleeding in 3 months prior dosing; 7. had surgery in four weeks prior dosing; 8. disease that affect drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction; 9. abdominal fistula, gastrointestinal perforation or intraperitoneal abscess in 6 months prior dosing; 10. urine protein ≥++, and urine protein ≥1.0g in 24 hours; 11. active infection and need antimicrobial treatments; 12. history of psychiatric substance abuse; 13. take any clinical trial drugs within four weeks prior dosing; 14. take any drugs that have effect on gastric acid and metabolic enzyme cyp 3a and cyp2d6; 15. combined with other viral infections (anti-hcv, anti-hiv positive, hbsag positive) or combined with syphilis infection; 16. addicted to alcohol and tobacco; 17. take grapefruit or grapefruit product, drinks containing caffeine, xanthine and alcohol in 48 hours prior dosing; 18. the investigator believes that the subjects are not eligible to participate in this trial.
a pilot study of 5-aminolevulinic acid (5-ala) to enhance visualization of pituitary adenomas

Conditions: Pituitary Adenoma

Summary: 5-aminolevulinic acid (5-ala) was approved by the fda as an intraoperative optical imaging agent in patients with suspected high-grade gliomas (hggs) in 2017. the investigators plan to administer 5-ala to patients with pituitary tumors to demonstrate whether it can be used as an intraoperative optical imaging agent for this pathology. overall, this pilot study will afford the overall opportunity to improve surgical management and advancement of the science of neurological and neuroendocrine disease.


Eligibility criteria:
inclusion criteria: * patients with non-functioning pituitary adenomas who require surgical intervention, as deemed appropriate by a neurosurgeon, either due to size criteria, observed growth in lesion on mri, and/or for alleviation of the symptoms of mass effect. * patients with functional pituitary adenomas, including prolactinomas, growth-hormone secreting adenomas, and acth-secreting adenomas, where surgery is recommended for biochemical control. patients with symptoms of cushing's disease and centralization of acth on ipss without imaging-confirmed lesions will be included in the study. exclusion criteria: * history of allergic reactions attributed to compounds of similar chemical or biologic composition to aminolevulinic acid (ala). patients should refrain from use of other potential phototoxic substances (e.g. tetracyclines, sulfonamides, fluoroquinolones, hypericin extracts) for 72 hours. * personal or family history of porphyria. * uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with 5-ala breastfeeding should be discontinued if the mother is treated with 5-aminolevulinic acid. * women who are pregnant or become pregnant will be excluded from the trial as it is unknown if aminolevulinic acid (ala) is teratogenic or has abortifacient effects. * prior history of gi perforation, diverticulitis, and/or peptic ulcer disease.
effects of wearable technology and smart phone applications based exercise training in patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to estimate the extent to which supported exercise training through wearable technology and mobile application affects glycemic control in comparison to supervised exercise training in patients with type-2 diabetes.

the purpose of this study is to estimate the extent to which supported exercise training through wearable technology and mobile application affects glycemic control in comparison to supervised exercise training in patients with type-2 diabetes. inclusion criteria: * age 18-65 * no other chronic condition * no exercise training background block randomization according to age and sex. confirmatory outcome - glycated hemoglobin (hba1c) explanatory outcomes * flexibility * level of physical activity - ipaq (mets) and accelerometer * hamstring / quad strength - isokinetic * grip strength * respiratory function test - f1, fvc, f25, f75, f100 * 6mwt * balance - static, dynamic, proprioception, sit-to-stand balance * body muscle percentage - bioelectrical impedance analysis

Eligibility criteria:
inclusion criteria: age 18-65 no other chronic condition no exercise training background exclusion criteria: * exclusion criteria are a set of predefined condition that is used to identify subjects who will not be included or who will have to withdraw from a research study after being included.

Keywords: diabetes mellitus, type 2 physical activity exercise behavior exercise smart phone wearable technology self-management glycated hemoglobin (hba1c)
a study of combination therapies to treat covid-19 infection

Conditions: COVID; COVID-19; Corona Virus Infection; Coronavirus Infection; Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere; Coronavirus-19; SARS-CoV 2; SARS Pneumonia

Summary: this study seeks to determine whether dual or quadruple therapy is more effective in treating covid-19.

in this study, patients will be administered either dual or quadruple therapy and have pcr tests run daily to determine efficacy as indicated by time to non-infectivity

Eligibility criteria:
inclusion criteria: 1. signed informed consent, demonstrating that the subject understands the procedures required for the study and the purpose of the study 2. healthy, ambulant male or female subjects 18 years of age to 65 years of age 3. positive test for covid-19 by rt-pcr at screening 4. subjects must agree to practice at least one highly effective method of birth control for the duration of the study. this includes condoms with spermicide, oral birth control pills, contraceptive implants, intra-uterine devices, or diaphragms. subjects not of reproductive potential will be exempt (e.g. post-menopausal, surgically sterilized) 5. subjects must agree they will do their best to attend the treatment facility daily for 10 days exclusion criteria: 1. refusal to sign informed consent form 2. negative test for covid-19 by rt-pcr at screening 3. severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature \> 38 degrees; pleuritic pain, or frequent cough. 4. known drug allergy to any of the investigational medications 5. currently taking medication with known drug interactions with investigational medications (listed in appendix) 6. prescription or other antiviral medications 7. any comorbidities which constitute health risk for the subject 8. pregnant or lactating females; 9. weight \< 110lb; 10. porphyria 11. established retinal disease 12. inability to attend daily for 10 days 13. any contraindications for treatment with hydroxychloroquine 1. hypoglycemia 2. known g6pd deficiency 3. porphyria 4. anemia 5. neutropenia 6. alcoholism 7. myasthenia gravis 8. skeletal muscle disorders 9. maculopathy 10. changes in visual field 11. liver disease 12. psoriasis 13. history of qt \>500msec 14. history of torsades de pointes 14. anemia from pyruvate kinase and g6pd deficiencies 15. abnormal ekg with qt prolongation acquired or from birth 16. history of jaundice or high fevers prior to developing covid-19 17. treatment with any of the medications listed in appendix ii 18. treatment with any anti-epileptic medication 19. treatment with any other drug not listed that affects the qt interval
evaluation of mailers promoting mammogram screening

Conditions: Breast Cancer

Summary: in this evaluation, 3 different versions of mailers promoting annual mammograms are being sent to women on the month of their 50th and 64th birthdays. the researchers hypothesize that the use of behavioral nudges in the mailers should lead to increased uptake in mammogram screening.

mammogram screening for women, starting at age 50, can significantly reduce the risk of complications due to breast cancer. as part of an existing outreach campaign, the health system mails a postcard and small gift (pink socks) to women on the month of their 50th and 64th birthdays to promote annual mammogram screening. the researchers are evaluating two new versions of the mailers against a standard mailer to see which version leads to greater uptake in mammograms. the new mailers have content that applies behavioral nudge theory - specifically, loss frames and fear appeals - to encourage taking action. one of the two new versions does not include the small gift, to test whether its inclusion or exclusion has any effect on mammogram screening.

Eligibility criteria:
inclusion criteria: * female geisinger health plan members turning 50 and 64 in that month * for the 2020 campaign, birthdays from june 2020 (as opposed to august 2020) will be included due to a temporary suspension of the outreach program due to the covid-19 pandemic since june * for the pre-post examination of the 2019 campaign, all months in that year will be included exclusion criteria: - members who are on the do not contact list at geisinger health plan

Keywords: mass screening communication mammography risk reduction behavior economics, behavioral psychology loss frame fear appeals reciprocity
triggering and protective factors of burnout in medical resident

Conditions: Burnout, Professional

Summary: residents and interns are prone to emotional and physical exhaustion, also known as burnout. burnout has not been studied much in physicians working in lower-middle income countries. we conducted this cross-sectional study at two institutes to determine the burden of burnout among internal medicine residents and to identify triggering and protective factors associated with burnout. an abbreviated version of the maslach burnout scale was used to measure burnout, and protective and triggering factors were recorded according to known factors.


Eligibility criteria:
inclusion criteria: - all residents of the internal medicine program at both institutes exclusion criteria: * residents who were part of a flexible training program, working in shifts and those who had done less than six months of training were excluded

Keywords: burnout residents medicine pakistan
to evaluate the safety and effectiveness of atorvastatin plus a cholinesterase inhibitor in ad patients.

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to find out if atovastatin, when taken with a cholinesterase inhibitor, is effective for treating alzheimer's disease.


Eligibility criteria:
inclusion criteria: * diagnostic evidence of probable alzheimer's disease consistent with nincds/adrda and dsm iv criteria. * subject's mini-mental status examination score (mmse) must be in the range of 13 - 25 (inclusive) at screening. exclusion criteria: * subjects with dementia due to causes other than alzheimer's disease. * any condition, which, in the investigator's judgment might increase the risk to the subject or decrease the reliability of the data required to meet the objectives of the study.
awake prone position to reduce ventilation inhomogeneity in covid-19 acute respiratory failure

Conditions: Respiratory Failure

Summary: evaluation of awake prone position on ventilation inhomogeneity in covid-19 associated respiratory failure.

awake prone position has been proposed as an additional treatment to alleviate hypoxemia during covid-19 acute respiratory failure and potentially to avoid in some case tracheal intubation and invasive ventilation. potential mechanism is improvement of ventilation: perfusion mismatch through redistribution of ventilation to the dorsal part of the lungs where perfusion is prominent. electrical impedance tomography (eit) is a non-invasive functional lung imaging of distribution of ventilation. therefore, we aim to assess eit on lung ventilation inhomogeneity during supine and prone position in covid-19 patients.

Eligibility criteria:
inclusion criteria: * more than 18 years (adult, older adult) * confirmed covid-19 (positive sars-cov-2 rt-pcr at nasopharyngeal swab) * acute respiratory failure with 100 \< pao2:fio2\< 300 mmhg * spontaneous ventilation with standard oxygen supply or high flow humidified oxygen * written informed consent of the patient exclusion criteria: * contra-indication to prone position including pregnancy * presence of pacemaker * severe hypoxemia with pao2/fio2 \< 100 mmhg * evidence of clinical signs of respiratory distress with high probability of intubation in the next two hours
observational study of vision improvement in patients with retinal disorders

Conditions: Age-related Macular Degeneration; Diabetic Macular Edema

Summary: the purpose of this study is to assess the vision improvement achieved by patients with retinal disorders who received corneal treatments by a low vision aid device.

the purpose of this study is to assess the vision improvement achieved by patients with retinal disorders, including age-related macular degeneration and diabetic macular edema, who received corneal treatments by a low vision aid device. patient records will be analyzed to determine measures of vision improvement including best spectacle-corrected distance visual acuity (cdva). analyses will include descriptive statistics and correlation between outcomes and baseline characteristics.

Eligibility criteria:
inclusion criteria: 1. - female or male 2. - any race 3. - patient is at least 50 years old 4. - patient has diagnosed retinal disorder that causes central vision loss in one or both eyes 5. - treated eyes, at time of treatment, were pseudophakic or phakic with no significant vision loss due to cataract 6. - patient had moderate to severe baseline vision impairment with cdva of 20/63 or worse (decimal = 0.317 or less; logmar greater than or equal to 0.50) in the treated eye(s) 7. - patient cdva records are available at baseline and at 1m or longer post-tx times exclusion criteria: 1 - corneal disease or disorder in either eye 2 - increased intraocular pressure (above 20mm hg), glaucoma or history of glaucoma 3 - presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable for retrospective observational study -

Keywords: age-related macular degeneration diabetic macular edema